Lower respiratory tract infections (LRTIs) remain the most common illnesses in children, accounting for up to two-thirds of pediatric outpatient and ...

Prescription drug costs continue to spiral upward, leaving employers scrambling to offer robust pharmacy benefits while keeping costs sustainable. Every year, tens of billions of dollars flow into ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Company launches the first-of-its-kind, AI-powered clinical trial feasibility platform to accelerate clinical trial startup – ...

Axuall, the industry leader in clinical workforce intelligence, and the world-renowned Cleveland Clinic today announced a ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today ...

The Bureau of Labor Statistics is calling some staff back to work to prepare its closely watched inflation gauge, the Consumer Price Index (CPI) report, despite the government shutdown, a Trump ...

RLF-OD032 demonstrated bioequivalence to KUVAN® PowderStudy results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF ...